Results 21 to 30 of about 184,499 (325)

Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer

Cell Death and Disease, 2021
The poor prognosis of pancreatic cancer is primarily due to the development of resistance to therapies, including gemcitabine. The long noncoding RNA PVT1 (lncRNA PVT1) has been shown to interact with enhancer of zeste 2 polycomb repressive complex 2 ...
Yan Sun, Dianyun Ren, Yingke Zhou, Jian Shen, Heshui Wu, Xin Jin   +5 more
doaj   +1 more source

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

Cancer Cell, 2017
Surendra K Shukla, Vinee Purohit, Kamiya Mehla   +2 more
exaly   +2 more sources

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

JAMA Network Open, 2023
Key Points Question Is there a difference in outcomes associated with sequential intravesical gemcitabine and docetaxel therapy vs bacillus Calmette-Guérin (BCG) therapy, the standard of care for the treatment of high-risk non–muscle-invasive bladder ...
I. McElree, Ryan L. Steinberg, S. Mott, M. O'Donnell, Vignesh T. Packiam   +4 more
semanticscholar   +1 more source

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer. [PDF]

, 2014
BackgroundPancreatic ductal adenocarcinoma has proven to be one of the most chemo-resistant among all solid organ malignancies. Several mechanisms of resistance have been described, though few reports of strategies to overcome this chemo-resistance have ...
Bold, Richard J, Daylami, Rouzbeh, Muilenburg, Diego J, Virudachalam, Subbulakshmi   +3 more
core   +2 more sources

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

Journal of Pharmacological Sciences, 2015
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters
Kentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo   +16 more
doaj   +1 more source

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. [PDF]

, 2016
Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic
Chen, Qiu-Dan, Ge, Xin, Jiang, Bing-Hua, Lin, Yong, Liu, Ling-Zhi, Lu, Yuan, Shi, Zhu-Mei, Wang, Min, Wen, Yiyang   +8 more
core   +2 more sources

Stearoyl-CoA desaturase 1 inhibitor supplemented with gemcitabine treatment reduces the viability and fatty acid content of pancreatic cancer cells in vitro

Journal of Pancreatology, 2021
. Objective:. Pancreatic cancer (PC) is an aggressive cancer with ineffective treatment. Inhibition of stearoyl-CoA desaturase 1 (SCD1) suppresses cancer proliferation and might act as a novel chemotherapy supplement, but this has not been investigated ...
Amon B. Hackney, Wen Y. Chung, John Isherwood, Ashley R. Dennison, Naomi Martin   +4 more
doaj   +1 more source

Barriers and opportunities for gemcitabine in pancreatic cancer therapy

American Journal of Physiology - Cell Physiology, 2022
Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-related deaths across the world. A lack of durable responses to standard-of-care chemotherapies renders its treatment particularly challenging and largely contributes ...
Alica K Beutel, Christopher J. Halbrook
semanticscholar   +1 more source

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine. [PDF]

, 2016
First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.
Barile, Elisa, Das, Swadesh K, De, Surya K, Emdad, Luni, Fisher, Paul B, Morvaridi, Susan Kharagh, Pandol, Stephen J, Pellecchia, Maurizio, Quinn, Bridget A, Sarkar, Devanand, Stebbins, John L, Wang, Si   +11 more
core   +2 more sources